Biocartis Group Equity 2024

Biocartis Group Aktienanalyse

What does Biocartis Group do?

Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Biocartis Group's Equity

Biocartis Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biocartis Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biocartis Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biocartis Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biocartis Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biocartis Group stock

What is the equity of Biocartis Group this year?

Biocartis Group has equity of -30.28 M EUR this year.

What was the equity of Biocartis Group compared to the previous year?

The equity of Biocartis Group has increased/decreased by -10.66% decreased compared to the previous year.

What impact does a high equity have on investors of Biocartis Group?

A high equity is advantageous for investors of Biocartis Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Biocartis Group?

A low equity can be a risk for investors of Biocartis Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Biocartis Group affect the company?

An increase in equity of Biocartis Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Biocartis Group affect the company?

A reduction in equity of Biocartis Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Biocartis Group?

Some factors that can affect the equity of Biocartis Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Biocartis Group so important for investors?

The equity of Biocartis Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Biocartis Group take to change the equity?

To change equity, Biocartis Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Biocartis Group pay?

Over the past 12 months, Biocartis Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocartis Group is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biocartis Group?

The current dividend yield of Biocartis Group is .

When does Biocartis Group pay dividends?

Biocartis Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biocartis Group?

Biocartis Group paid dividends every year for the past 0 years.

What is the dividend of Biocartis Group?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biocartis Group located?

Biocartis Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biocartis Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biocartis Group from 10/7/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Biocartis Group pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Biocartis Group in the year 2023?

In the year 2023, Biocartis Group distributed 0 EUR as dividends.

In which currency does Biocartis Group pay out the dividend?

The dividends of Biocartis Group are distributed in EUR.